-
Something wrong with this record ?
HPMA copolymer conjugates of DOX and mitomycin C for combination therapy: physicochemical characterization, cytotoxic effects, combination index analysis, and anti-tumor efficacy
H. Kostková, T. Etrych, B. Ríhová, L. Kostka, L. Starovoytová, M. Kovář, K. Ulbrich,
Macromolecular bioscience.
2013 ;
13 (12) :
1648-60.
Language English Country Germany
Document type Journal Article, Research Support, Non-U.S. Gov't
Persistent link
https://www.medvik.cz/link/bmc14074662
- MeSH
- Acrylamides chemistry MeSH
- Survival Analysis MeSH
- Lymphoma, B-Cell drug therapy mortality pathology MeSH
- Cytotoxins chemistry pharmacology MeSH
- Disulfides MeSH
- Doxorubicin chemistry pharmacology MeSH
- Carcinoma, Lewis Lung drug therapy mortality pathology MeSH
- Carcinoma drug therapy mortality pathology MeSH
- Kinetics MeSH
- Drug Therapy, Combination MeSH
- Levulinic Acids chemistry MeSH
- Lymphoma, T-Cell drug therapy mortality pathology MeSH
- Mitomycin chemistry pharmacology MeSH
- Mammary Glands, Animal drug effects pathology MeSH
- Mice, Inbred C57BL MeSH
- Mice MeSH
- Cell Line, Tumor MeSH
- Drug Carriers chemical synthesis MeSH
- Antineoplastic Agents chemistry pharmacology MeSH
- Neoplasm Transplantation MeSH
- Tumor Burden drug effects MeSH
- Animals MeSH
- Check Tag
- Mice MeSH
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
The synthesis, characterization and results of evaluation of the biological behavior of HPMA copolymer conjugates bearing anti-cancer drugs doxorubicin and mitomycin C are described. Two HPMA copolymer carrier types were synthesized: the linear copolymer and the biodegradable high-molecular-weight diblock copolymer containing a degradable disulfide bond. The polymer-drug conjugates incubated in buffers modeling the intracellular environment released the drugs more rapidly than those incubated in bloodstream conditions. Significant in vitro and in vivo antitumor synergistic activity of the conjugates in the treatment of EL-4 T-cell demonstrates their high potential for solid tumor treatment.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc14074662
- 003
- CZ-PrNML
- 005
- 20141009093533.0
- 007
- ta
- 008
- 141006s2013 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/mabi.201300288 $2 doi
- 035 __
- $a (PubMed)24031022
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Kostková, Hana $u Institute of Macromolecular Chemistry Academy of Sciences of the Czech Republic, v.v.i., Heyrovsky Sq. 2, 162 06, Prague 6, Czech Republic.
- 245 10
- $a HPMA copolymer conjugates of DOX and mitomycin C for combination therapy: physicochemical characterization, cytotoxic effects, combination index analysis, and anti-tumor efficacy / $c H. Kostková, T. Etrych, B. Ríhová, L. Kostka, L. Starovoytová, M. Kovář, K. Ulbrich,
- 520 9_
- $a The synthesis, characterization and results of evaluation of the biological behavior of HPMA copolymer conjugates bearing anti-cancer drugs doxorubicin and mitomycin C are described. Two HPMA copolymer carrier types were synthesized: the linear copolymer and the biodegradable high-molecular-weight diblock copolymer containing a degradable disulfide bond. The polymer-drug conjugates incubated in buffers modeling the intracellular environment released the drugs more rapidly than those incubated in bloodstream conditions. Significant in vitro and in vivo antitumor synergistic activity of the conjugates in the treatment of EL-4 T-cell demonstrates their high potential for solid tumor treatment.
- 650 _2
- $a akrylamidy $x chemie $7 D000178
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a protinádorové látky $x chemie $x farmakologie $7 D000970
- 650 _2
- $a karcinom $x farmakoterapie $x mortalita $x patologie $7 D002277
- 650 _2
- $a karcinom plic Lewisové $x farmakoterapie $x mortalita $x patologie $7 D018827
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a cytotoxiny $x chemie $x farmakologie $7 D003603
- 650 _2
- $a disulfidy $7 D004220
- 650 _2
- $a doxorubicin $x chemie $x farmakologie $7 D004317
- 650 _2
- $a nosiče léků $x chemická syntéza $7 D004337
- 650 _2
- $a kombinovaná farmakoterapie $7 D004359
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a kinetika $7 D007700
- 650 _2
- $a kyseliny levulové $x chemie $7 D007982
- 650 _2
- $a B-buněčný lymfom $x farmakoterapie $x mortalita $x patologie $7 D016393
- 650 _2
- $a lymfom T-buněčný $x farmakoterapie $x mortalita $x patologie $7 D016399
- 650 _2
- $a mléčné žlázy zvířat $x účinky léků $x patologie $7 D008321
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a myši inbrední C57BL $7 D008810
- 650 _2
- $a mitomycin $x chemie $x farmakologie $7 D016685
- 650 _2
- $a transplantace nádorů $7 D009368
- 650 _2
- $a analýza přežití $7 D016019
- 650 _2
- $a tumor burden $x účinky léků $7 D047368
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Etrych, Tomáš
- 700 1_
- $a Ríhová, Blanka
- 700 1_
- $a Kostka, Libor
- 700 1_
- $a Starovoytová, Larisa
- 700 1_
- $a Kovář, Marek
- 700 1_
- $a Ulbrich, Karel
- 773 0_
- $w MED00006593 $t Macromolecular bioscience $x 1616-5195 $g Roč. 13, č. 12 (2013), s. 1648-60
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/24031022 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20141006 $b ABA008
- 991 __
- $a 20141009093921 $b ABA008
- 999 __
- $a ok $b bmc $g 1042545 $s 873574
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 13 $c 12 $d 1648-60 $i 1616-5195 $m Macromolecular bioscience $n Macromol Biosci $x MED00006593
- LZP __
- $a Pubmed-20141006
